Active Lecithin Cholesterol Acyltransferase (LCAT) Mus musculus (Mouse) Active protein

phosphatidylcholine-sterol O-acyltransferase; Phospholipid-cholesterol acyltransferase

Add to Cart Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 90%
  • Isoelectric Point6.3
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Lecithin Cholesterol Acyltransferase (LCAT) Packages (Simulation)
  • Active Lecithin Cholesterol Acyltransferase (LCAT) Packages (Simulation)
  • Active Lecithin Cholesterol Acyltransferase (LCAT) Figure . Gene Sequencing (extract)
  • APJ516Mu01.jpg Figure. SDS-PAGE; Sample: Active recombinant LCAT, Mouse.
  • Active Lecithin Cholesterol Acyltransferase (LCAT) Figure. Western Blot; Sample: Recombinant LCAT, Mouse.
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

LCAT (Phosphatidylcholine-sterol acyltransferase) is an enzyme in the extracellular metabolism of plasma lipoproteins, which converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines. It is reported that APOA1 (Apolipoprotein A-I) acts as a cofactor for the LCAT. Thus, a binding ELISA assay was conducted to detect the association of LCAT with APOA1. Briefly, recombinant rat LCAT were diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to APOA1-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-LCAT pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of LCAT with APOA1 was shown in Figure 1 and this effect was in a dose dependent manner.

Usage

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Plasma phospholipase, γ‐CEHC and antioxidant capacity in fibromyalgiaPubMed: 26585319
  • Alteration of Lysophosphatidylcholine-Related Metabolic Parameters in the Plasma of Mice withExperimental Sepsis.pubmed:28028754
  • A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.pubmed:28664912
  • Lipid-lowering effects of medium-chain triglyceride-enriched coconut oil in combination with licorice extracts in experimental hyperlipidemic micePubmed: 30244576
  • Identification and validation of differentially expressed proteins in serum of CSU patients with different duration of wheals using an iTRAQ labeling, 2D‑LC‑MS/MSDoi: 10.3892/etm.2018.6818
  • Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.Pubmed: 31388184
  • The synergistic mechanism of total saponins and flavonoids in Notoginseng− Safflower pair against myocardial ischemia uncovered by an integrated …Pubmed: 32739736
  • Pharmacokinetics/pharmacometabolomics-pharmacodynamics reveals the synergistic mechanism of a multicomponent herbal formula, Baoyuan decoction?¡­
  • Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progressionPubmed:35235775

Recommend products